Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

Andrew J. Armstrong, Susan Halabi, Patrick Healy, Joshi J. Alumkal, Carolyn Winters, Julie Kephart, Rhonda L. Bitting, Carey Hobbs, Colleen F. Soleau, Tomasz M. Beer, Rachel Slottke, Kelly Mundy, Evan Y. Yu, Daniel J. George

    Research output: Contribution to journalArticlepeer-review

    37 Scopus citations

    Fingerprint

    Dive into the research topics of 'Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer'. Together they form a unique fingerprint.

    Medicine & Life Sciences